Plant molecular farming is the practice of producing recombinant proteins, secondary metabolites, and other non-naive proteins in plants that have commercial, biological, and therapeutic value. The basis of this technology is the genetic modification of plants, which can be achieved using both stable gene transfer techniques (gene transfer to nuclei and chloroplasts) and unstable transfer techniques (viral vectors). The manufacturing of biomedicine is limited by its high cost and inefficient production methods. However, transgenic plants have drawn a lot of attention as bioreactors of new generation due to its benefits, including the safety of recombinant antibodies, enzymes, vaccines, growth factors and their potential for the large-scale low-cost production. Amplification and spread of the transgene, buildup of recombinant protein toxicity in the environment, contamination of the food chain, and the expenses of further processing are some alarming problems associated with the use of transgenic plants. To produce useful products like enzymes, pharmaceutical proteins, and biomedicines via the safest, cheapest, and most effective means, plants are appropriate by expressing functional proteins that are identical to those found in mammals. Additionally, from interleukins to recombinant antibodies, plants can produce therapeutic proteins in huge quantities. Plant suspension cell culture in fermenters or field multiplication of plant lines undergone stable transformation can enhance the amount of protein and biomass generated by plants.